# OnCo record paper-mountaineer-lancet-oncol-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-mountaineer-lancet-oncol-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-mountaineer-lancet-oncol-2023" ;
  schema:name "MOUNTAINEER: tucatinib plus trastuzumab for HER2-positive, RAS wild-type metastatic colorectal cancer"@en ;
  schema:description "The chemotherapy-free combination of tucatinib and trastuzumab shrank tumours in almost four in ten patients with previously treated HER2-positive colorectal cancer, with responses lasting about a year, and became the first approved HER2 regimen for the disease."@en ;
  schema:url <https://onco.cc/key-papers/paper-mountaineer-lancet-oncol-2023/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(23)00150-X>, <https://pubmed.ncbi.nlm.nih.gov/37142372/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(23)00150-X> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Strickler JH, Cercek A, Siena S, et al." ;
  onco:cancers <https://onco.cc/cancers/her2-amplified-colorectal/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/tucatinib/> ;
  onco:trials <https://onco.cc/trials/mountaineer/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .